Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022
Reunion Neuroscience Inc., previously known as Field Trip Health Ltd., announced that its common shares will start trading on the Toronto Stock Exchange under the symbol 'REUN' on August 17, 2022. This trading marks the final step in a corporate reorganization, which included the spinout of its subsidiary, Field Trip Health & Wellness Ltd. Reunion holds a 21.84% stake in this subsidiary. The company specializes in developing innovative psychedelic-inspired therapeutics, focusing on mental health treatments such as RE-104, aimed at postpartum and treatment-resistant depression.
- Commencement of trading on Toronto Stock Exchange under 'REUN'.
- Successful completion of corporate reorganization, enhancing focus on core operations.
- Retention of a 21.84% interest in the spun-out subsidiary, potentially valuable.
- No immediate financial metrics were disclosed to assess market impact.
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or “Reunion”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “REUN” at the opening of the market on August 17, 2022.
Trading of the Company’s shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company’s former subsidiary, Field Trip Health & Wellness Ltd. (“FTHW”) into a stand-alone public company listed on the TSX Venture Exchange. Reunion continues to hold a
For further details on the business of the Company, please refer to the management information circular dated May 20, 2022 and the supplement thereto available on its SEDAR and EDGAR profiles available at www.sedar.com or https://www.sec.gov/edgar.
About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
Learn more at https://www.investors.reunionneuro.com, and https://www.reunionneuro.com.
Follow us on Twitter and Instagram: @reunionneuro.
Cautionary Note Regarding Forward-Looking Information
This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
CONTACTS:
Reunion Neuroscience:
Joseph del Moral
joseph@reunionneuro.com
Media contacts:
McKenna Miller / Nick Opich
KCSA Strategic Communications
reunion@kcsa.com
Investor contacts:
Phil Carlson / Sophia Bashford
KCSA Strategic Communications
reunion@kcsa.com
SOURCE Reunion Neuroscience Inc.
FAQ
When will Reunion Neuroscience start trading on the TSX?
What is the significance of the corporate reorganization for Reunion Neuroscience?
What therapeutic areas does Reunion Neuroscience focus on?
What is RE-104 and its purpose?
What percentage of Field Trip Health & Wellness does Reunion hold?
